India Issues Urgent Warning as Low-Cost Weight-Loss Drug Generics Flood the Market
India is at the center of a pharmaceutical revolution—and a potential public health challenge. With the recent expiration of patents on semaglutide, the active ingredient in globally recognized weight-loss drugs such as Ozempic and Wegovy, India’s generics market is poised to offer affordable alternatives that could transform the fight against obesity. Yet, the Ministry of […]
Continue Reading